CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 991	$ 6,933	$ 3,126	$ 13,098
Operating expenses:
Cost of goods sold		1,418	620	4,008
Research and development	9,308	30,310	31,272	54,644
General and administrative	6,408	7,545	13,224	14,436
Restructuring	2,581		4,982
Total operating expenses	18,297	39,273	50,098	73,088
Operating loss	(17,306)	(32,340)	(46,972)	(59,990)
Other income, net	689	861	1,641	1,846
Loss on inventory write-down	(1,489)		(1,489)
Non-cash interest expense on liability related to sales of future royalties and milestones	(1,910)		(3,892)
Net loss	$ (20,016)	$ (31,479)	$ (50,712)	$ (58,144)
Net loss per share:
Basic	$ (0.37)	$ (0.58)	$ (0.93)	$ (1.08)
Diluted	$ (0.37)	$ (0.58)	$ (0.93)	$ (1.08)
Weighted average shares:
Basic	54,724,692	54,002,988	54,656,391	53,937,875
Diluted	54,724,692	54,002,988	54,656,391	53,937,875
Other comprehensive income, net of tax of $0:
Change in unrealized gains on available-for-sale marketable securities	$ 70	$ 371	$ 139	$ 942
Total comprehensive loss	(19,946)	(31,108)	(50,573)	(57,202)
Collaborative revenue
Revenue:
Total revenue		5,410	788	8,160
Commercial supply revenue
Revenue:
Total revenue		1,400	640	4,591
Royalty revenue
Revenue:
Total revenue		$ 123		248
Clinical compound revenue
Revenue:
Total revenue			84	$ 99
Other revenue
Revenue:
Total revenue	$ 991		$ 1,614